Related Experiment Videos
Optimizing syngeneic orthotopic murine bladder cancer (MB49)
J H Günther1, A Jurczok, T Wulf
1Department of Urology, Medical University of Lübeck, Germany.
Cancer Research
|June 26, 1999
Summary
Optimizing the MB49 mouse bladder cancer model improves tumor implantation reliability. Prolonged tumor cell dwell time ensures 100% tumor take and maintains sensitivity to Bacillus Calmette-Guérin immunotherapy.
Area of Science:
- Urology
- Oncology
- Immunology
Background:
- The MB49 syngeneic orthotopic murine bladder cancer model is crucial for preclinical research.
- However, unreliable tumor implantation in this model hinders consistent experimental outcomes.
Purpose of the Study:
- To optimize the MB49 murine bladder cancer model for enhanced reliability in tumor implantation.
- To verify if the modified model retains sensitivity to topical immunotherapy.
Main Methods:
- A modified transurethral instillation technique was employed, prolonging tumor cell dwell time to 3 hours.
- Three groups of mice received varying MB49 cell counts (50,000, 20,000, or 10,000).
- Tumor take rates, survival, and bladder weights were assessed; immunotherapy efficacy was tested using Bacillus Calmette-Guérin (BCG).
Main Results:
- The modified technique achieved 100% tumor take rates across all tested cell concentrations.
- Survival and bladder weights showed significant correlation with the number of instilled tumor cells.
- BCG treatment significantly improved survival and reduced bladder weights compared to phosphate-buffered saline (PBS) controls, even with a high tumor load.
Conclusions:
- The optimized MB49 model demonstrates high reliability for tumor implantation.
- This enhanced model maintains its responsiveness to topical immunotherapy, making it suitable for preclinical bladder cancer studies.